The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.

Amlitelimab, a fully human non-T cell depleting monoclonal antibody that selectively targets OX40-ligand (OX40L), is safe and ...

On-body injector delivery of subcutaneous teprotumumab achieves clinically meaningful proptosis reduction in phase 3 thyroid eye disease study.

In the new subcutaneous drug delivery landscape, the growing trend towards patient-friendly, at-home administration is ...

Learn how subcutaneous nivolumab shifts immunotherapy from IV infusions to quick thigh or abdominal injections, approved in late 2024.

Amgen AMGN announced positive top-line results from a late-stage study evaluating the subcutaneous (under the skin or SC) ...

Medically reviewed by Marla Anderson, MD Key Takeaways IV therapy delivers cancer medicine directly into a vein and often ...

As drugmakers strive to fine tune the delivery of their medications for better convenience and patient adherence, Halozyme is putting a recent acquisition in the space to work, thanks to a new tie- | ...

The biotechnology company said Monday that its under-the-skin version of Tepezza met its primary endpoints in treating moderate-to-severe thyroid eye disease, showing a 77% proptosis response rate, ...

Argenx has filed for FDA approval of subcutaneous efgartigimod, keeping it on track to start selling the sibling of its existing intravenous generalized myasthenia gravis (gMG) treatment Vyvgart. In ...

Elegrobart is a subcutaneously-administered monoclonal antibody designed to target and inhibit the IGF-1 receptor, a key driver of thyroid eye disease.

A subcutaneous version of the newly approved Alzheimer's drug lecanemab (Leqembi) may be on the horizon. Weekly subcutaneous lecanemab 100 mg/mL injection appeared to be as effective at amyloid plaque ...